Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility

Table 3 Total savings from patent expiration during 2020–2024 for various scenarios

Scenario	Budget savings			Changes from base case savings
Scenario	Korea (₩): million	US ($): million	% of expenditures^a	Korea (₩): million	US ($): million	(%)
Base case	₩234,429	$203	20%
Based on group B cancer drugs	₩157,633	$136	14%	- ₩76,795	-$66	−33%
Based on group C cancer drugs	₩434,523	$376	38%	₩200,095	$173	+ 85%
Generic entrance: 6 months delay	₩165,904	$144	14%	- ₩68,524	-$59	−29%
Risk-sharing scheme rebate of 25%	₩221,465	$192	19%	-₩12,963	-$11	−6%
Adjustment for reimbursement	₩210,985	$183	18%	- ₩23,443	-$20	−10%
Growth of off-patent market	₩255,316	$221	22%	₩20,888	$18	+ 9%
Price level of originators	₩206,929	$179	18%	-₩27,499	-$24	−12%
Price levels of generics/biosimilars	₩234,771	$203	20%	₩343	$0	0%
New pricing policy (July 2020)	₩246,082	$213	21%	₩11,654	$10	+ 5%

^a The proportion of budget savings was calculated by dividing budget savings for each scenario by the 5-year total expenditure for the base case (₩1,145,470 million)

ISSN: 1472-6963